Please provide your email address to receive an email when new articles are posted on . In an analysis of the ISAR-CLOSURE trial, use of vascular closure devices was as safe and effective as manual ...
In patients undergoing transfemoral coronary angiography and percutaneous coronary intervention (PCI), use of a vascular closure device results in reduced rates of complications compared with manual ...
In general, use of a vascular closure device after transfemoral percutaneous coronary intervention (PCI) decreases the risk of vascular complications, according to a large registry study of real-world ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. LAS VEGAS — In a comparison of two vascular closure ...
LAS VEGAS -- Bleeding complication risk after transcatheter aortic valve replacement (TAVR) isn't the same between two of the most commonly used femoral vascular closure devices, one study showed, ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Results from a Cordis analysis presented at the 14 th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) congress in Madrid indicates ...
BURLINGTON, MA — An active surveillance system now available as an open-source tool found that the relative risk of vascular complications was increased 60% for patients receiving Mynx (Cardinal ...
Patients who underwent surgery to repair punctured arteries had a significantly higher risk of complications when surgeons used a vascular-closure device manufactured by Cardinal Health, compared to ...
Irish devicemaker Vasorum got FDA approval for its Celt ADC vascular closure device that is aimed at arterial puncture closure. The device is indicated for both diagnostic and anticoagulated ...
DUBLIN, Nov. 11, 2020 /PRNewswire/ -- The "Vascular Closure Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027" report has been added to ResearchAndMarkets ...
Earlier this week, Needham downgraded Haemonetics from “Buy” to “Hold,” pointing to intensifying competition in vascular closure devices from Abbott and Cordis and warning that this could weigh on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results